勋章金融(MDLN)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 MDLN 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement FY 2025
Item	Category	Value	YoY
Net sales	revenue	28.43B	11.47%
Gross profit	profit	7.52B	7.77%
Cost of goods sold	cost	20.91B	12.86%
Operating income	profit	2.21B	3.08%
Total operating expense	cost	5.31B	9.86%
Income before income taxes	profit	1.25B	0.16%
Total other expense	revenue	964.00M	7.11%
Selling, general and administrative expenses	cost	4.52B	10.13%
Amortization of intangible assets	cost	704.00M	2.77%
Other operating income (expense), net	revenue	78.00M	110.81%
Net loss attributable to noncontrolling interests	cost	2.00M
Net income	profit	1.16B	-3.58%
Provision for income taxes	cost	91.00M	97.83%
Interest expense, net	revenue	812.00M	-6.02%
Foreign exchange (loss) gain, net	revenue	88.00M	1157.14%
Other (expense) income, net	revenue	64.00M	48.84%
Other comprehensive income (loss)	revenue	32.00M	1.18%
Net income attributable to medline inc.	profit	1.16B
Comprehensive loss attributable to noncontrolling interests	cost	2.00M
Total comprehensive income	profit	1.19B	16.23%
Comprehensive income attributable to medline inc.	profit	1.19B	16.42%

Business Breakdown
Segment	Value	YoY
Supply Chain Solutions	14.71B	13.24%
Medline Brand	13.72B	9.63%

Geography Breakdown
Segment	Value	YoY
UNITED STATES	26.48B	11.50%
Non-US	1.95B	10.97%

Balance Sheet FY 2025
Item	Category	Value	YoY
Intangible assets, net	assets	13.89B	-4.57%
Goodwill	assets	8.08B	0.17%
Inventories	assets	4.77B	7.02%
Trade accounts receivable, net of allowance for credit losses of $152 and $108 as of december 31, 2025 and 2024, respectively	assets	3.53B	9.75%
Cash and cash equivalents	assets	1.94B	874.37%
Deferred tax assets	assets	583.00M
Other long-term assets	assets	472.00M	-3.08%
Other current assets	assets	438.00M	10.05%
Total other non-current assets	assets	23.03B	-0.36%
Total current assets	assets	10.68B	29.10%
Property, plant, and equipment, net	assets	4.78B	3.98%
Total assets	assets	38.48B	6.97%
Total stockholders’ equity / partners’ capital	liabilities	19.29B
Total liabilities	liabilities	19.20B	-1.32%
Noncontrolling interests	liabilities	8.55B
Accumulated deficit	equity	7.00M
Total medline inc. stockholders’ equity	equity	10.74B
Total non-current liabilities	liabilities	16.71B	-1.80%
Total current liabilities	liabilities	2.49B	2.05%
Aggregate	equity	10.74B
Long-term borrowings, less current portion	liabilities	12.48B	-23.95%
Tax receivable agreement liability	liabilities	3.54B
Other long-term liabilities	liabilities	682.00M	14.05%
Accrued expenses and other current liabilities	liabilities	1.45B	-2.75%
Accounts payable	liabilities	961.00M	10.59%
Current portion of long-term borrowings and other short-term borrowings	liabilities	77.00M	-1.28%
Additional paid-in capital	equity	10.72B
Accumulated other comprehensive income	equity	27.00M	145.45%

Operating Activities – 12M 2025
Item	Value
Net income	1.16B
Depreciation and amortization	1.01B
Stock-based compensation expense	76.00M
Accounts payable	73.00M
Non-cash lease expense	72.00M
Unrealized gain (loss), foreign currency transaction, before tax	68.00M
Amortization of deferred financing costs	59.00M
Gain (loss) on extinguishment of debt	58.00M
Credit losses	54.00M
Other noncash income (expense)	13.00M
Other liabilities	-19.00M
Embedded derivative, gain (loss) on embedded derivative, net	-41.00M
Accrued expenses and other current liabilities	-92.00M
Increase (decrease) in other operating assets	-126.00M
Increase (decrease) in inventories	-264.00M
Increase (decrease) in accounts receivable	-355.00M

Investing Activities – 12M 2025
Item	Value
Payments to acquire businesses, net of cash acquired	6.00M
Payments for asset acquisitions	-33.00M
Payments to acquire property, plant, and equipment	-447.00M

Financing Activities – 12M 2025
Item	Value
Proceeds from long-term borrowings	7.57B
Proceeds from issuance of class a common stock in initial public offering, net of underwriting discounts and commissions	7.05B
Proceeds from lines of credit	179.00M
Payments for repurchase of common stock	-33.00M
Payments of stock issuance costs	-36.00M
Repayments under lines of credit	-179.00M
Payments of capital distribution	-518.00M
Payments for purchase of redemptions of common units from pre-ipo common unitholders, initial public offering	-1.97B
Repayments of other long-term debt	-11.66B

Cash Balance – 12M 2025
Item	Value
Cash and cash equivalents, beginning of period	250.00M
Cash and cash equivalents, end of period	1.94B